Latest news

  • 19 January 2021

    Sensorion announces preclinical data demonstrating SENS-401’s potential to preserve residual hearing after cochlear implantation. Read

  • 18 January 2021

    Half-year report on the Sensorion liquidity contract with Kepler Cheuvreux. Read

  • Company

    Sensorion combines world-class, scientific excellence and top-tier execution capabilities to deliver first-in-class therapeutics as a “pure player” focused on debilitating inner ear disorders. Read more

  • Pipeline

    Sensorion has one clinical stage drug candidate for sudden sensorineural hearing loss, two preclinical gene therapy programs and a cutting-edge inner ear R&D platform. Read more

  • Investors

     Sensorion is focused on addressing treatment needs for 140 million of patients suffering from debilitating inner ear disorders having limited treatment options. Read more